
Tribunal sides with disabled woman denied ultrasound at Calgary clinic
An Alberta woman who filed a human rights complaint after being turned away at a clinic for an ultrasound says she hopes her recent win paves the way for better accommodations for disabled patients.
Stephanie Chipeur complained to the Alberta Human Rights Tribunal after the Calgary diagnostics clinic refused to schedule her for an appointment in 2021 unless she had a caretaker also attend to lift her from her wheelchair onto an exam table.
Chipeur says she is quadriplegic and has been in a wheelchair since she injured her spinal cord in a car crash.
'They said we won't be able to give you an appointment, because we don't do anything to do with transfers. So I was kind of like, this is not OK,' said Chipeur, a law professor at the University of Calgary.
'I talked to my doctor about this refusal, and she was like, 'Yeah, this happens to my patients all the time.''
The tribunal ruled this week that the clinic, run by EFW Radiology, discriminated against Chipeur.
She was awarded $15,000 in damages, commissioner Erika Ringseis said in the written decision.
The decision says Chipeur's physiatrist told her to get a deep vein ultrasound to assess a possible blood clot. When Chipeur called to set up an appointment, she was told by the clinic that staff couldn't lift patients onto the exam table, and she would need to bring a caregiver.
Asked about using a mechanical lift, the clinic told Chipeur only a hospital had such equipment.
'I thought it was reasonable that they should — I would expect at least one of their 12 locations in Calgary would have a lift,' Chipeur said.
Chipeur said she got an ultrasound in a hospital, but then had to get a second of a different type a month later — one that she could only get at the clinic because the hospital didn't have the staff, the decision says.
'The complainant faced an untenable situation where she believed that she was being denied all opportunity to get the necessary MSK ultrasound,' Ringseis says in the decision.
A friend later referred Chipeur to a small clinic that did the ultrasound as she sat in her wheelchair.
'It was clear to the tribunal member that it was so obvious that they could have been more accommodating, and they just were being difficult,' Chipeur said.
At the tribunal hearing, the clinic argued staff were not permitted to lift patients due to safety risks and that Chipeur didn't experience an 'adverse impact' with the denial.
Ringseis disagreed.
'The complainant was denied a service by the respondent, which resulted in a delay before she could receive a necessary ultrasound,' she says.
'The inconvenience and loss of time associated with needing to schedule an alternative location is an adverse impact, even if the complainant was able eventually to receive the ultrasound.'
Dr. David Lautner from EFW Radiology said in a statement that the clinic has updated its policies and procedures, including the addition of steps to support patients who need help being transferred to exam tables.
'We recognize that the experience of this specific patient in 2021 did not reflect the high standards of accessibility and patient care we are committed to providing,' Lautner said.
'We continue to proactively evaluate and invest in additional equipment to further enhance accessibility. Our goal is to ensure equitable, barrier-free access to diagnostic care for all patients.'
Chipeur said she's happy the tribunal sided with her and hopes diagnostic clinics take steps to accommodate people with disabilities.
'This decision, I needed it, so that all of the clinics wouldn't be able to say no to people like me anymore,' she said.
This report by The Canadian Press was first published July 18, 2025.
Aaron Sousa, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
15 minutes ago
- CTV News
‘Do not consume': Recall expanded for this cheese brand over possible listeria contamination
The Canadian Food Inspection Agency has expanded its recall for Mount Becher Buffalo Medium Cheese on July 21, 2025. (Canadian Food Inspection Agency) Canadian consumers are being warned to not eat a cheese product that may be contaminated with the bacteria Listeria monocytogenes. The Canadian Food Inspection Agency (CFIA) has expanded its recall for Mount Becher Buffalo Medium Cheese to include various sizes sold in British Columbia with the batch number 854 179. The CFIA previously posted the advisory on June 24 about a 150-gram product that was distributed in Ontario with a best before date of Oct. 2, 2025, and the batch number 854 263. 'Do not consume, use, sell, serve, or distribute recalled products,' the CFIA stated in its latest notice about the product posted online Monday. 'Recalled products should be thrown out or returned to the location where they were purchased.' How serious is the recall? Although listeria infection is rare, it's serious, according to the U.S. Centers for Disease Control and Prevention. The CFIA has designated the updated recall of Mount Becher Buffalo Medium Cheese at Class 1, the highest risk level that could lead to 'serious health problems or death.' 'The CFIA is verifying that industry is removing recalled products from the marketplace,' according to the notice. The CFIA said its test results triggered the recall. It is also conducting a food safety investigation, which it said may lead to more recalls. No illnesses linked to eating this product were reported as of Monday, it added. Advice for consumers The CFIA recommends consumers who become ill from eating the cheese to see their health-care provider. Symptoms include vomiting, nausea, persistent fever, muscle aches, severe headache and neck stiffness, it added. 'Food contaminated with Listeria monocytogenes may not look or smell spoiled but can still make you sick,' according to the notice. Those most at risk are pregnant women, the elderly and people with weakened immune systems, the notice stated. 'Although infected pregnant women may experience only mild, flu-like symptoms, the infection can lead to premature delivery, infection of the newborn or even stillbirth,' the CFIA wrote. 'In severe cases of illness, people may die.'


CTV News
26 minutes ago
- CTV News
What you need to know about West Nile, Rocky Mountain spotted fever and the measles
Video Infectious diseases expert Dr. Isaac Bogoch on what you need to know about West Nile, Rocky Mountain spotted fever and the Measles.

National Post
an hour ago
- National Post
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
Article content SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. Article content 'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. Article content 'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.' Article content The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. Article content CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Article content About CyPath® Lung Article content CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit Article content About bioAffinity Technologies, Inc. Article content bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Article content Forward-Looking Statements Article content Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Article content Article content Article content Article content Article content Contacts Article content bioAffinity Technologies Article content Article content Julie Anne Overton Article content Article content Director of Communications Article content Article content